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The use of human pluripotent stem cells (PSCs) for cell therapy faces a number of
challenges that are progressively answered by results from clinical trials and experimental
research. Among these is the control of differentiation before transplantation and the
prediction of cell fate after administration into the human brain, two aspects that condition
both the safety and efficacy of the approach. For neurological disorders, this includes two
steps: firstly, the identification of the optimal maturation stage for transplantation along
the continuum that transforms PSCs into fully differentiated neural cell types, together
with the derivation of robust protocols for large-scale production of biological products,
and, secondly, the understanding of the effects of environmental cues and their possible
interference with transplanted cells commitment. This review will firstly summarize our
knowledge on developmental processes that have been applied to achieve robust in vitro
differentiation of PSCs into neural progenitors. In a second part, we summarize results
from experimental and clinical transplantation studies that help understanding the dialogue
that establishes between transplanted cells and their host brain.
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Pluripotent stem cells (PSCs) are defined by the ability to self-
renew indefinitely in a controlled environment and to form cells
of all organs after guided (in vitro) or natural (in vivo) dif-
ferentiation. PSC include embryonic stem cells (ESC; Thomson
et al., 1998) and induced pluripotent SC (iPSC; Takahashi and
Yamanaka, 2006). Human (h) iPSC and hESC share the same abil-
ity to differentiate along the neural lineage (Karumbayaram et al.,
2009) and are considered appropriate cell sources for stem cell
(SC) therapy in neurological disorders. In some reports, hiPSC
have shown a greater variability in neural differentiation prop-
erties than hESC (Hu et al., 2010). However, recent technical
improvements have reduced these variations (Chambers et al.,
2009; Hu et al., 2010), emphasizing the importance of envi-
ronmental cues in neural commitment. The definition of the
ideal therapeutic product for intracerebral transplantation is also
restricted by the fact that, on the one hand, fully differentiated
neurons do not survive transplantation and, on the other hand,
undifferentiated PSC usually form teratoma after transplantation
if not rejected by the recipient immune system. The optimal ther-
apeutic product is a still ill-defined intermediate, described as a
“neural stem cell” (NSC), a “neural precursor cell” (NPC), or
a neural progenitor, without accurate characterization of each
phenotype.
The brain contains billions of neurons that connect one with
another in complex networks and are grouped according to anato-
mical and functional criteria into hundreds of sub-populations.
Ideally, cell replacement therapy should aim at transplanting
neuronswith phenotype(s) identical to the one(s) destroyed by the
pathology or the insult. This requirement varies according to the
disorder (Rossi and Cattaneo, 2002). Neurodegenerative diseases
involve progressive destruction—at least in the first steps of the
disease—of amainneuronal population, e.g., ventral telencephalic
dopaminergic neurons in Parkinson’s disease, striatal GABAergic
medium spiny neurons in Huntington’s disease, or motoneurons
in amyotrophic lateral sclerosis. Besides neuronal populations,
demyelinating diseases such asmultiple sclerosiswould require the
replacement of glial cells, namely oligodendrocytes that sharewith
neurons and astrocytes a common progenitor. In these cases, the
replacement of a single cell type would theoretically be sufficient
to limit the clinical consequences of the disease, and efforts have
been put on the development of differentiation protocols aimed
at increasing the yield of the corresponding population (Perrier
et al., 2004; Keirstead et al., 2005; Shin et al., 2005). In contrast,
acute brain lesions or diffuse, aspecific, degeneration, as found
after trauma, stroke, genetic diseases with stroke, or vascular
dementias, are characterized by the destruction of heterogeneous
cell populations with variable identities according to the lesion
site. The identification of the final therapeutic product is thus
less clear-cut and might even include neural and non-neural
cell populations, such as mesoderm-derived microglia and blood
vessel-forming cells.
After transplantation, NSC, NPC, or progenitors, can be dif-
ferentially affected by the changes that abruptly occur in their
environment. Defining the role of the environment on the fate of
transplanted neural cells is a highly demanding task that has been
approached in several disease models and is still rudimentary.
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This goal might never totally be reached if one considers the
importance of the temporal dimension and related constant adap-
tation of the cerebral milieu during the course of a disease. These
are particularly crucial in acute brain lesions with breaches in the
blood-brain barrier that lead to a profound and rapidly evolving
transformation of the parenchymal milieu.
In conclusion, the development of a bioproduct for PSC ther-
apy relies, firstly, on their propensity to be instructed before trans-
plantation and, secondly, to their reaction to dramatic changes
in environmental cues after transplantation. The development of
efficient grafts requires (1) the definition of needed cell type(s)
according to the pathology, (2) the definition of the intermediate
cell type able to sustain transplantation, and (3) the elaboration
of protocols amenable to standardization for large-scale clinical
application, including amplification and storage steps. Here we
discuss how our knowledge from embryogenesis has been applied
to PSC to develop neural intermediates with clinical relevance,
and how experimental and clinical studies can help us under-
standing the modifications of pre-transplantation commitment
by the lesioned brain environment.
THE FIRST STEPS OF NEURAL COMMITMENT: LESSONS
FROM EMBRYOGENESIS
FROM PLURIPOTENCY TO NEUROPOTENCY
Obtaining specific neuronal or glial populations has to proceed
through two essential steps. Firstly, pluripotent cells must be com-
mitted into the neural lineage to the first population of neural
progenitors found in the neural plate, the neuro-epithelial cells.
Secondly, still primitive and plastic neuro-epithelial cells must be
regionally patterned to restrict their potential into the requested
type of neuron or glial cell.
Until recently, most of the neural induction protocols used for
the conversion of PSC into neuro-epithelial cells relied on the for-
mation of embryonic bodies or on the co-culture of PSC with
mesenchymal stromal cell lines. Stromal cell lines, such as the PA6
or MS-5 murine lines, have strong neural-inducing properties
(Kawasaki et al., 2000). Using these methods, human PSCsmay be
coaxed along the neural lineage to differentiate into a population
of bipolar neuro-epithelial cells that express the main markers of
the neural tube, Pax6 and Sox1 (Perrier et al., 2004; Watanabe
et al., 2005). This organization, named “rosette,” morphologi-
cally and molecularly mimics the developing neural tube (Zhang
et al., 2001; Ying et al., 2003) (Figure 1). Embryoid bodies and
rosette-related strategies have considerable drawbacks, including
poorly defined culture conditions and concomitant production
of undesired cell types. The later requires an additional step
of cell sorting to obtain more homogenous populations. This
procedure also requires the use of cells and components from
animal origin. A step forward to clinical application was made
by Lowell and collaborators, who demonstrated that hPSC can
adopt a neural lineage in adherent, feeder-free, monolayer cul-
ture with a fully defined medium (Lowell et al., 2006). Still, this
“default” differentiation protocol lacked efficacy and did not solve
the problem of heterogeneity, leading to a mixture of Pax6/Sox1
neuro-epithelial cells and of still undifferentiated Oct4/TRA1-60-
positive cells that remained refractory to induction. This indi-
cated that additional developmental cues had to be identified and
FIGURE 1 | Commitment of hPSC along the neural lineage. (A) Phase
contrast morphology of a colony of undifferentiated pluripotent hESC
(arrow) cultivated on a feeder layer of mouse fibroblast (star). (B) After eight
days of treatment with the BMP antagonist Noggin and the Activin inhibitor
SB431542, structures resembling the neural tube are clearly identifiable.
Neuro-epithelial cells form an epithelium (arrow) surrounding a lumen (star).
Scale bar: 100μm.
applied in vitro to promote full commitment of hPSC into neural
progenitors.
The formation of early embryonic tissues is the result of a
tightly controlled sequence of events in which the cellular envi-
ronment, or niche, plays an instrumental role. Embryonic tissues
secrete molecules that coax stem cells and progenitors toward a
specific lineage. In the nervous system, the earliest NPC is found
in the neuroectoderm, arising from the central part of the prim-
itive ectoderm after the appearance during gastrulation of the
notochord, one of organizer mesodermal structures (Harland,
2000). Noggin, an antagonist of the bone morphogenetic pro-
tein (BMP) receptors, was one of the first identified instructive
proteins that play a crucial role during the formation of the neu-
roectoderm. Noggin is secreted by notochord cells. By blocking
BMP-dependent pathways, Noggin instructs surrounding ecto-
dermic cells to adopt a more specialized neural fate, ending up
in the formation of the neural plate (Smith and Harland, 1992;
Lamb et al., 1993; Zimmerman et al., 1996). However, it recently
emerged that inhibition of BMP-dependent pathways by their
endogenous inhibitors Noggin, Follistatin, or Chordin, is not suf-
ficient to completely induce neuralization in vertebrates. BMP
molecules exert their neural-suppressing activity by activating
the kinase domain of their specific receptors and inducing the
phosphorylation of two receptor-associated proteins Smad5 and
Smad1. Once activated, Smad5/1 propagates the signaling cas-
cade by binding to the co-factor Smad4 and translocating to the
nucleus to exert a pro-transcriptional activity. This might indicate
that wider blockage of pathways that activate the transcription
factors of the Smad family is required to fully control the neural
induction process.
In agreement, complete neuralization is obtained with dual
inhibition of BMP pathways, which act through the Smad1/5-
dependent cascade, and of the activin/nodal pathway, which
signals through Smad2/3 as receptor-linked proteins (Bell et al.,
2003; Linker and Stern, 2004; Chang and Harland, 2007). In
2009, Chambers and collaborators used a combination of BMP
and the Smad-dependent transforming growth factor β (TGFβ)
pathways to fully achieve neural conversion of human embryonic
and iPSC lines into Pax6-positive cells. When used to destabilize
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TGF/activin- and Nanog-mediated pluripotency networks, the
TGFβ receptor inhibitor SB431542 suppresses mesendodermal
fates by inhibiting endogenous activin and nodal signals. Neural
conversion of the resulting ectodermal cells was achieved with
addition of the BMP inhibitor Noggin. The obtained neuro-
epithelial cells were competent to form neural rosettes and could
further be differentiated into mesencephalic dopaminergic neu-
rons and spinal motoneurons (Chambers et al., 2009). This
approach is fully amenable to clinical grade production since it
avoids serum and cells of animal origin.
REGIONAL PATTERNING OF PSC-DERIVED NEURO-EPITHELIAL CELLS
In addition to the acquisition of an early neural fate, cells aimed at
therapeutic purposes must be differentiated into restricted, neu-
ral or glial, progenitors. Failure to do so results in formation of
adverse structures after transplantation (see below).
During neurogenesis, the potential of each cell to adopt a
specific phenotype differs according to its position along the
rostro-caudal and dorso-ventral (DV) axis. Early region-specific
molecular programming is essential to the existence of diver-
gent structures in the brain. In mammal embryos, the anterio-
posterior (AP) axis is specified as gastrulation and neurulation
proceed. The closing neural tube quickly divides into three pri-
mary vesicles: the anterior forebrain, the midbrain, and the
posterior hindbrain. The forebrain will further sub-divide into
two structures, the rostral telencephalon and the diencephalon
(Pombero andMartinez, 2009), whereas the caudal hindbrainwill
form the rhombencephalon and the spinal cord. Secondary pat-
terning sequences will further specify DV domains inside each
structure (Lupo et al., 2006). The organization of these secondary
vesicles prefigures the future brain structures. The telencephalon
will give rise to the cortex in its dorsal part and to anterior
basal ganglia including the caudate and the putamen in its ven-
tral part. The thalamus and hypothalamus will emerge from the
ventral diencephalon, the substantia nigra (SN) from the ventral
mesencephalon, the cerebellum from the dorsal domain of the
rhombencephalon, and spinal motor neurons will form from the
ventral part of the spinal cord. The potential of a given population
of progenitors to produce specific neurons is tightly dependent on
the position of these progenitor cells along the AP and DV axes of
the developing nervous system. Here again, extra-cellular signals
provide a group of neural progenitors with the unique compe-
tency to produce specific neuronal or glial subtypes. The activity
of these signals are spatiotemporally integrated by neural pro-
genitors to determine the specific combinations of transcription
factors activated in distinct AP and DV compartments of the CNS
(Vieira et al., 2010). Elucidation of the molecular basis of regional
patterning is a sine qua non condition to efficiently commit hPSC-
derived naïve neuro-epithelial cells to produce the desired type of
end-product.
The most potent factor for induction of a caudal neural tube
fate is retinoic acid, a lipophilic molecule derived from vitamin A
(Durstonetal., 1989;Papalopuluetal., 1991;Blumbergetal., 1997).
Retinaldehyde dehydrogenases (Raldh), the enzymes that control
RA synthesis, are activated in somites, leading to a gradual release
of RA along the posterior part of the neural tube (Molotkova et al.,
2005).RApassivelydiffuses across the target cell plasmamembrane
and binds to its nuclear receptors RARs. Binding leads to the
activation of retinoic acid responsive element (RARE)-dependent
genes. In the posterior neural tube, RA activates the caudal genetic
program that relies on Hox homeodomain genes, leading to the
formation and further regionalization of the hindbrain and the
spinal cord. Other caudalizing factors include members of the
fibroblast growth factor (FGF) family and Wnts. However, these
molecules have milder effects that mainly rely on the intrinsic
ability of the neural cells to respond to these factors, a process
that may itself be controlled by RA (Ogura and Evans, 1995;
Bel-Vialar et al., 2002). The most anterior part of the neural tube
is considered to adopt a rostral fate by default (Rallu et al., 2002).
However, this anterior fate can be promoted by exposition of
early neuro-epithelial cells to inhibitors of the BMPs, Noggin and
Chordin, and by inhibitors of the Nodal pathway, Cripto and
Cerberus (Lamb et al., 1993; Hemmati-Brivanlou et al., 1994;
Bouwmeester et al., 1996; Bachiller et al., 2000; Liguori et al.,
2009), indicating some degree of specificity for these factors.
DV patterning of the neural tube mainly results from a balance
between the antagonized actions of members of the sonic hedge-
hog (SHH) family. SHH family members were first isolated in the
early 1990s and act as bona fide morphogenetic signals to deter-
mine the ventral progenitor identity (Lee et al., 1992; Echelard
et al., 1993; Tashiro et al., 1993). Cleavage of SHH releases
two secreted proteins that correspond to the 19 kDa N-terminal
and the 25 kDa C-terminal domains. The N-terminal of SHH
mediates all signaling activities in vertebrates and invertebrates
(for review see Hammerschmidt et al., 1997). SHH N-terminus
domain binds its transmembrane receptor Patched at the cell
surface of competent cells, thus releasing the constitutive inhibi-
tion of the adjacent trans-membrane factor Smoothened (Smo).
Within the nucleus of the responding cell, zinc-finger transcrip-
tion factors of the Gli family act at the last step of the SHH signal
transduction pathway (Hynes et al., 1997; Ruiz i Altaba, 1998).
The region specific combinatory effect of Gli2 activation and Gli3
repression by SHH in different areas of the neural tube deter-
mines the regional result on neural patterning (Zervas et al., 2004;
Blaess et al., 2006). During the nervous system development, SHH
molecules are secreted in the ventral part of the embryo by cells
located inside the neural floor plate and by the surrounding noto-
chord. A gradient of SHH along the DV axis will be transduced
into a gradient of intracellular Gli activity, which can account
for the morphogen activity of SHH by inducing the combinato-
rial expression of the transcription factors that ultimately defines
the identity of the neural progenitor cell (Stamataki et al., 2005).
Dorsally, SHH activities are counteracted by BMPs and Wnts.
BMPs are required for the correct specification of dorsal cell types
and may act by both desensitizing target cells to SHH signal and
sustaining the activity of the SHH-repressed Gli-3. In addition,
the Wnt canonical pathway also restricts SHH signaling via a
direct effect on Gli-3 and by inducing BMP expression.
LOCAL PATTERNING: THE FINAL SPECIFICATION
A number of developmental molecules have been successfully
applied on PSC-derived neuro-epithelial cells to produce a
variety of neuronal progenitor populations and, subsequently,
neuronal types relevant for cell replacement strategies. From
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progenitor pools of the forebrain, the main neurons of inter-
est are glutamatergic cortical projection neurons, GABAergic
interneurons and projection neurons, and cholinergic neu-
rons. Oligodendrocytes add a non-neuronal, although neural,
population.
Telencephalic populations
Glutamatergic projection neurons of the neo-cortex result from
the terminal differentiation of progenitors located in the pal-
lium, or immature cortex progenitors, on the dorsal part of
the telencephalon. As described above, anterior fates have been
obtained from PSC using default protocols in the absence of
any morphogens (Li et al., 2009; Zeng et al., 2010). The result-
ing population of neural progenitors express high levels of the
anterior marker FoxG1 and can be further patterned dorsally or
ventrally using the interplay between Wnt and SHH pathways.
Further differentiation of primitive neuroepithelial cells in the
absence of SHH spontaneously produce neural progenitors that
express the dorsal markers Pax6 and Emx1 but do not express the
ventral markers Gsh-2 and Nkx2.1. In hPSC, this spontaneous
dorsal fate can be actively promoted by high levels of endoge-
neous Wnt molecules that are produced by human cells during
the first weeks of differentiation. When terminally differentiated
in vitro, these progenitor cells ultimately generate early Tbr1 and
Ctip2 positive cortical neurons (Li et al., 2009; Zeng et al., 2010).
This default dorsal fate can be challenged by exposition of the
neuro-epithelial cells to SHH and by inhibiting the Wnt pathway
in order to obtain forebrain ventral progenitors. Major types of
neurons are generated from ventral forebrain progenitors located
in the ganglionic eminence. GABAergic medium spiny neurons
of the striatum, and cholinergic neurons of the basal forebrain,
originate from the lateral (LGE) and medial ganglionic eminence
(MGE), respectively. The main GABAergic interneurons originate
from both (Olsson et al., 1998; Letinic et al., 2002). Treatment
of neuro-epithelial rosettes with SHH and the inhibitor of the
Wnt pathway Dickkopf 1 (DKK1) almost completely converts the
Pax6-expressing dorsal precursors into ventral progenitors that
express Gsx2 and Nkx2.1 (Aubry et al., 2008; Li et al., 2009).
Fine-tuning of SHH and Wnt gradients can further discrimi-
nate LGE or MGE progenitor fates from hPSC. In the presence of
low concentrations of SHH, the obtained progenitors exhibit the
phenotype of LGE cells, with expression of Gsx2 and low levels
of Pax6, but no expression of the more ventral marker Nkx2.1.
Upon SHH removal, these LGE-like progenitors differentiate into
GABAergic neurons that display glutamic acid decarboxylase,
the dopaminergic receptor-1 second messenger DARPP32, and
the striatal marker Meis2 (Aubry et al., 2008). In contrast, in the
presence of high concentrations of SHH, the dorsal transcrip-
tion factors, Pax6, and Emx1, are completely repressed, and the
ventral transcription factor Nkx2.1 is upregulated. Using these
conditions, one can generate a progenitor population enriched in
the MGE phenotype with repression of the LGE markers Meis2
and Gsx2 and homogeneous expression of Nkx2.1. MGE-like
progenitors give rise in vitro to GABAergic interneurons and pro-
jection cholinergic neurons that express the choline acetyltrans-
ferase (ChAT) enzyme and the vesicular acetylcholine transporter
VAchT (Liu and Zhang, 2010).
Mesencephalic populations
The midbrain dopaminergic (mDA) neuron has been a prime
target in stem cell research and developmental neurobiology,
owing to its role in Parkinson’s disease. DA neurons responsible
for movement control are mainly located in the SN and the ven-
tral tegmental area (VTA) in the midbrain. DA neurons derive
from progenitors located in the floor plate of the ventral part of
the embryonic midbrain (Ono et al., 2007). Accordingly, most
protocols that aim at deriving DA neurons progenitors from
hPSC rely on the exposition of early neuro-epithelial to SHH
and to FGF-8, a weak but sufficient caudalizing factor (Perrier
et al., 2004; Andersson et al., 2006; Friling et al., 2009; Rhee
et al., 2011; Swistowski et al., 2011). Recently, the small molecule
CHIR99021, a glycogen synthase kinase (GSK)-3 inhibitor, has
been identified as a more potent caudalizing agent that FGF-8,
and has been used to produce high yields of mDA in combina-
tion with a modified form of SHH. The early ventral midbrain
specification firstly characterizes by the activation of the mid-
brain marker En-1 and the floor plate marker FoxA2, and the
absence of the forebrain marker FoxG1 (Fasano et al., 2010; Kriks
et al., 2011). Upon progression through a more restricted DA
fate, these progenitors express the typical transcription factors
Nurr-1 and Pitx-3, as observed during mammalian develop-
ment. In agreement, Nurr-1 and Pitx3 cooperatively promote
terminal differentiation of human and murine ESC into DA neu-
rons (Martinat et al., 2006). In the presence of the pro-survival
factor brain derived neurotrophic factor (BDNF), DA neuron
progenitors produce tyrosine hydroxylase-positive but dopamine
β-hydroxylase-negative neurons, indicating their potential to syn-
thesize monoamines but not norepinephrine, hence DA. After
transplantation, these DA neurons could correct neurological
deficit in two different animal models of Parkinson’s disease,
which fully validates their functionality (Kriks et al., 2011; Rhee
et al., 2011).
Serotonin has important functions in the etiology and treat-
ment of a number of psychiatric diseases (Hedlund, 2009).
Like DA neurons, serotonergic neurons are located around the
boundary between the midbrain and hindbrain and might be
regulated by similar developmental signals, including SHH (Ye
et al., 1998). Adding SHH in the last stages of differentiation
of ESC dramatically increases the yield of serotonergic neurons
(Lee et al., 2000).
Spinal cord motoneurons
The progenitors of the spinal cord motor neurons represent
another attractive source of cells relevant for replacement ther-
apy. Spinal cord motor neurons originate from the motoneuron
progenitor domain located in the ventral developing spinal cord
(Soula et al., 2001). In order to obtain efficient spinal motor
neurons in vitro, primitive neuro-epithelial cells need to be cau-
dalized as the neural induction proceeds, using high concen-
trations of RA. The expression of genes from the Hox family,
particularly Hoxb4, Hoxb9, Hoxc5, and Hoxc8, sign the poste-
rior fate of the resulting progenitor. In parallel, ventralization of
the caudal neuroepithelium with SHH limits the cells to a ventral
spinal fate, includingOlig2-expressing motor neuron progenitors.
After several weeks of patterning, factor withdrawal generates
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HB9-expressing post-mitotic motor neurons that express the full
pattern of motor neuron transcription factors, including Lhx3
and Isl (Soundararajan et al., 2006; Li et al., 2008). Further culture
of these neurons with the growth factors GDNF, BDNF and NT-
3, leads to their partial maturation characterized by expression
of the specific enzymes ChAT and VAChT that are responsible for
the synthesis of acetylcholine and primary function of motor neu-
rons at the nerve-muscle interface. Co-culture of human motor
neurons with a primary culture of myocytes induces clustering
of acetylcholine receptors on myotubes, as revealed by bungaro-
toxin staining, suggesting that these motor neurons are functional
and able to innervate their natural target organ. Transplantation
of human ESCs-derived motor neurons into chick embryonic
spinal cord and mouse spinal cord showed survival of grafted
neurons and phenotypic features of spinal cord motor neurons
(Lee et al., 2007). However, the functionality of hESC-derived
motor neurons in vivo has not yet been fully demonstrated.
Derived in ESC, these differentiation protocols have been suc-
cessfully transferred to iPSC (Karumbayaram et al., 2009). SHH
has also been replaced by purmorphamine, a small molecule ago-
nist with the ability to bind Smo. This modification improves the
efficacy of the protocol and produces over 50% HB9-expressing
motor neurons. It also bypasses the use of recombinant proteins,
thus facilitating the translation of the protocol to industrial and
clinical applications (Li et al., 2008).
Oligodendrocytes
Demyelination is a key component in the pathogenesis of many
neurologicaldisordersincludingmultiplesclerosis,traumaticbrain
and spinal cord injuries, and Alzheimer’s disease (Lassmann,
2009). Transplantation ofmyelinating cellsmay offer a therapeutic
approach to restore neurological function in these diseases by both
blocking secondary axonal degeneration and restoring axonal
transmission (Erceg et al., 2010; Nori et al., 2011; Yasuda et al.,
2011). Oligodendrocytes represent the myelinating cells of the
CNS.Oligodendrocyteprecursorcells(OPCs)aregeneratedduring
embryogenesis from the ventral part of the CNS and, in the adult
CNS, in response to brain or spinal cord injuries (Zhang et al.,
1999). In the telencephalon, OPC are generated in the MGE
and migrate laterally and dorsally to colonize other telencephalic
areas, including the neocortex (Vallstedt et al., 2005; Battiste et al.,
2007). Inthediencephalon,OPCformedintheventralpartmigrate
secondarily to their target sites, including the thalamus and the
cerebellum (Kessaris et al., 2006). Spinal OPCmainly derive from
neural progenitors located in the same territories than MN in the
ventral part of the developing spinal cord. The major inductive
morphogenetic signal for the appearance of OPCs in the ventral
region of the spinal cord and the telencephalon is SHH (Nicolay
et al., 2007). However, analysis of oligodendrogenesis in Shh−/−
knock-out mice has shown that OPCs are also generated in the
spinal cordand forebrain inaSHH-independentmanner, although
dependent on FGF2 (Kessaris et al., 2004; Cai et al., 2005). In
addition to FGF2, blockage of BMP-dependent signaling pathways
maybe involved. BMPantagonizes SHH-induced oligodendrocyte
specification,andinhibitionofBMPsignalingissufficienttoinduce
OPC formation both in vivo and in vitro (Lachapelle et al., 2002;
Vallstedt et al., 2005).
Alternative pathways may be responsible for OPC production
in the injured adult CNS. Intraperitoneal injection of FGF2 but
also platelet-derived growth factor AB (PDGFAB) has been shown
to promote the differentiation of adult NSC into OPC (Lachapelle
et al., 2002). In vivo, insulin-like growth factor 1 (IGF1) produced
by local astrocytes andmicroglia in response to demyelination can
instructadultneuralprogenitorcellsinthehippocampustobecome
oligodendrocytes byupregulating antagonists ofBMP(Hsieh et al.,
2004). A large number of studies have demonstrated that mouse
ESC can be directed to an OPC fate and further differentiated
as myelinating oligodendrocytes. Propagation of PSC-derived
neural precursors in medium containing either FGF2/EGF or
FGF2/PDGF yields homogenous populations of glial progeni-
tors capable of forming oligodendrocytes (Billon et al., 2002).
Alternatively, oligodendrocytes can be derived by RA-induced ES
cell differentiation (Liu et al., 2000). Both methods induce the
formation of OPC and oligodendrocytes that survive and engraft
upon transplantation into the demyelinated immature and adult
CNS where they myelinate axons. Several protocols using timely
exposureofNSCto factors includingSHH,EGF,FGF2, andNoggin
has been successfully developed to produce large amount of func-
tional oligodendrocytes from human PSCs (Glaser et al., 2005;
Nistor et al., 2005; Kang et al., 2007; Hu et al., 2009; Sundberg
et al., 2011).
TURNING A CELL CULTURE INTO A THERAPEUTIC PRODUCT
Restorative approaches after brain lesion intuitively require
from therapeutic products to reflect the diversity and speci-
ficity of missing cell populations. In practice, efforts are usu-
ally driven toward the main population affected by the disease,
i.e., GABAergic and glutamatergic neurons for cortical lesions,
GABAergic medium spiny neurons for striatal lesions (stroke
and Huntington’s disease), DA neurons for Parkinson’s disease,
motoneurons for spinal lesions, and ALS and oligodendrocytes
for demyelinating diseases. Major issues in using neural progen-
itors for intracerebral transplantation are, firstly, the selection of
robust differentiation protocols to produce safe grafts and, sec-
ondly, maintenance of the pre-transplantation commitment in
the diseased environment. Finally, the degree of integration of
grafted cells is of relevance to restore impaired circuits.
REQUIREMENT ONE: SAFETY
A main concern for cell replacement therapy with PSC is total
eviction of the risk to generate adverse structures in the recipient
brain. Adverse structures materialize in two forms, teratoma and
masses of hyperproliferative NSC called “overgrowths” (Wernig
et al., 2004; Mitjavila-Garcia et al., 2005; Brederlau et al., 2006;
Roy et al., 2006; Aubry et al., 2008). Non-malignant teratoma
are defined by the presence of tissue derivatives from at least two
different germ layers and are generated through high, although
transient, proliferation of undifferentiated cells. A systematic
analysis of the fate of grafted cells according to their in vitro, pre-
transplantation, maturation stage revealed that teratoma form
only with cultures at the early neuroepithelial stage. These cul-
tures are highly heterogeneous and contain cells with detectable
levels of pluripotency genes (Seminatore et al., 2010). Limited
differentiation after embryoid bodies or rosette formation might
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also lead to formation of cystic cavities that indicate an ectoder-
mal fate (Aubry et al., 2008; Seminatore et al., 2010). Strategies
developed to eliminate the risk of teratoma include sorting of
neural progenitors to exclude insufficiently differentiated cells
(Chung et al., 2006; Fukuda et al., 2006), dilution of transplanted
cells (Björklund et al., 2002; Inden et al., 2004), transformation of
cells to express suicide genes (Aebischer et al., 1996) or, more sim-
ply, improvement of differentiation protocols (Kim et al., 2002;
Tabar et al., 2005; Brederlau et al., 2006; Bühnemann et al., 2006;
Dihné et al., 2006; Guillaume et al., 2006; Daadi et al., 2008;
Seminatore et al., 2010). The latter is obviously the most reliable
for accurate up-scaling of progenitors production.
Teratoma formation might also depend on the graft vs.
host immunological distance. Transplantation in a mouse-to-rat
xenograft situation seemed to lessen ESC pluripotency and abil-
ity to form tumors in comparison to a mouse-to-mouse situation
(Erdö et al., 2003). This poses a major safety problem for allo-
genic transplantation in humans. However, studies in cynomol-
gousmonkeys with allogenic transplantation of ESC-derived NPC
revealed no adverse structures and a clear functional benefit
(Muramatsu et al., 2009). Further studies in large animals would
be needed to clarify this point.
Overgrowth corresponds to the hyperproliferation of neural
cells after transplantation. Overgrowths are observed after graft-
ing early NSC, close to the rosette stage, that keep in vivo the high
proliferative capacity that characterizes them in vitro (Roy et al.,
2006; Aubry et al., 2008). Although the resulting cell types are
exclusively neural, graft overgrowth might compress and destroy
surrounding host tissue. Like teratoma, overgrowths are elimi-
nated by extended differentiation over the last hyperproliferative
wave in vitro, that is also observed during development (Zhang
et al., 2001; Seminatore et al., 2010).
Cellmasses that canbe assimilated toovergrowthofnon-neural
cells have been reported after intracerebroventricular infusion of
autologous bone marrow-derived SC (BMSC) in severe experi-
mental autoimmuneencephalomyelitis (EAE), amodelofmultiple
sclerosis (Grigoriadis et al., 2011). Masses were not observed in
similar experimental conditions either in animals with mild EAE
(Grigoriadis et al., 2011), suggesting a role of the inflammatory
status of recipient animals, nor after infusion of neonatal NPC,
suggesting a cell-specific effect. This effect was not observed
by others (Siatskas et al., 2010; Harris et al., 2012) in similar
models. However, collagen deposition and axonal injury were
reported after administration of BMSC in a model of spinal
lesion (Hunt et al., 2008). Thus far, no major adverse effects
were reported in pilot treatments of multiple sclerosis and ALS
patients with intrathecal or intravenous delivery of autologous
BMSC (Mohyeddin et al., 2007; Karussis et al., 2010; Yamout
et al., 2010).
REQUIREMENT 2: KEEPING THE IN VITRO COMMITMENT AFTER
TRANSPLANTATION
After transplantation, cells have to face the heterogeneous envi-
ronment of the lesioned or diseased brain. Cells withdrawn from
totally defined and constant culture conditions must compose
after transplantation with a complex milieu, highly unstable and
rich in factors susceptible to modulate their fate. Grafted cells will
also have to face cellular and molecular components of the host
immune system that will tend to eliminate them.
Lessons from adult neurogenesis and the niche concept
The most striking example of successful survival and differenti-
ation of NSC in the brain is adult neurogenesis. Neurogenesis
in the adult brain occurs mainly in two discrete areas, the walls
of the lateral ventricle and the dentate gyrus of the hippocampal
formation (Altman, 1962; Sierra et al., 2011). Areas of adult neu-
rogenesis contain all instructive cues for life-long maintenance
of this precious pool of cells, and are therefore called “niche.” In
pathological conditions, neural SC responds to modifications of
cerebral homeostasis by modifying their proliferation and migra-
tion patterns (Moyse et al., 2008). In the SVZ, the particular
location of NSC (the type B cells), with processes apposed to both
the cerebrospinal fluid and blood vessels, makes them particularly
sensitive to changes triggered at distant sites. As in rodent, NSC
in the human SVZ niche live in close proximity with blood vessels
and the ependyma (Quinones-Hinojosa and Chaichana, 2007).
As a result, molecular cues derived from blood, cerebrospinal
fluid, endothelial and glial cells, and axonal afferents that ter-
minate into the niche can modulate the behavior of neurogenic
neuroblasts (Moyse et al., 2008; Tavazoie et al., 2008) and, likely,
of transplanted progenitors (Onteniente and Polentes, 2011).
Ependymal cells release noggin, an inhibitor of the BMP path-
way that regulates the proliferation and differentiation of adult
SVZ NSC (Kokovay et al., 2008; Zhao et al., 2008). Noggin is used
in vitro to promote the differentiation of pluripotent SC into early
neural progenitors (Itsykson et al., 2005; Sonntag et al., 2007).
Enhancing the supportive niche function after transplantation
might have a positive impact on transplant survival and influ-
ence fate decisions of transplanted progenitors. Growth factors,
neurotransmitters and SHH are other secreted proteins that regu-
late proliferation and differentiation of NSC in vitro and enhance
neurogenesis in both hippocampus and SVZ (Moyse et al., 2008).
Interestingly, after transplantation into the medial part of the
striatum, NPC were found into the adjacent SVZ, where they
adopted the fate and destination of SVZ-derived migrating neu-
ronal precursors (Tabar et al., 2005). Preferential homing to the
SVZ was also reported by Hoehn and collaborators after trans-
plantation of neural cells into the striatum (Hoehn et al., 2002).
This suggests that the niche formed by areas of adult neurogen-
esis is attractive to exogenous neuronal precursors and is able to
influence their fate to produce neurons with characteristics close
to the endogenous ones. In contrast, repeated demonstration of
the presence of a variety of neuronal types in intrastriatal grafts
from NPC, including GABAergic (Seminatore et al., 2010) and
dopaminergic (Kriks et al., 2011) neurons, show that the influence
of the neurogenic niche is limited or, at the least, that the degree
of modulation varies according to the extent of lineage restric-
tion before grafting. Here again, the pre-transplantation degree
of differentiation and homogeneity of transplanted populations
are instrumental.
Lessons from experimental studies
The exact composition of the external milieu after brain lesion
or during neurodegenerative diseases is far from being known,
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although some insights were provided by large-scale genomic
data (Sharp et al., 2011). Pleiotropic factors like FGF2, EGF, or
IGF1, which are released during brain insults, are known to reg-
ulate NSC proliferation to an ill-defined extent. Most trophic
factor-triggered signal transduction pathways share a common
denominator, the serine-threonin kinase Protein Kinase B, also
named Akt (Brazil and Hemmings, 2001). Besides its canoni-
cal role in cell survival, Akt is expressed in neural progenitors
(Owada et al., 1997) and is involved in NSC proliferation through
regulation of p21 (Rossig et al., 2001) and mTOR (Navé et al.,
1999). In vivo overexpression of Akt enhances proliferation of
NSC through a p21-independent, mTOR-dependent, pathway
(Sinor and Lillien, 2004). According to these observations, the
presence of FGF2 or EGF in the environment of transplanted cells
might favor a NSC state, with associated dangers of phenotypic
regression and generation of a highly proliferative graft. In addi-
tion, the effects of FGF family members on neural differentiation
from embryonic NPCs depend on the concentration of the factor.
Low concentrations have been reported to improve cell survival,
while higher concentrations promote proliferation (Ray et al.,
1997; Kelly et al., 2003). The resulting effects on transplanted cells
can hardly be predicted on the basis of these data, and most of
our knowledge come from empirical testing in transplantation
paradigms.
An example of the role of environmental signals has been
recently provided by Joannides and collaborators (Joannides
et al., 2007). ESC-derived NSC were grafted into the neonatal
rat brain, the uninjured adult rat brain, and the adult rat spinal
cord with gliotoxic demyelination. Authors observed that matu-
ration of NSC was delayed after engraftment into the uninjured
neonatal brain, in comparison with the maturation kinetics of the
cells in vitro. Grafting into the striatum after excitotoxic lesion
accelerated maturation, although no terminally differentiated
GABAergic medium spiny neurons were observed. Grafting into
the demyelinated spinal cord resulted in exclusive astroglial dif-
ferentiation. No neurons or oligodendrocytes were observed, con-
trasting with the predominant neuronal differentiation observed
in vitro. These results show that the micro-environment does
influence both lineage commitment and temporal maturation
of grafted NSC. However, this influence does not include the
last maturation stages of grafted cells and, most unfortunately,
does not promote the requested phenotypes. Similar results were
obtained after grafting NSC from hESC into the striatum of
6-hydroxydopamine-treated rats, with a reduced tendency to pro-
duce DA neurons compared to their behavior in vitro (Ben-Hur
et al., 2004), and in a focal demyelination paradigm (Tabar
et al., 2005). Here, NPC grafted into the non-lesioned brain
displayed extensive migration into the host parenchyma and dif-
ferentiated into neural cell types, including oligodendrocytes.
Transplantation into a demyelinating lesion did not change the
overall differentiation profile of grafted cells. Myelinating oligo-
dendrocytes were found in the presence or absence of demyeli-
nating insult, showing that the environment had little effect on
neural precursors. Contrasting results were reported using imma-
ture neuro-epithelial cells, characterized by expression of Sox1,
Pax6, and Ki67, grafted into the neonatal mouse brain (Guillaume
et al., 2006).
The discrepancies observed in these studies very likely come
from the differentiation protocol and maturation stage of cells at
the time of transplantation, two critical parameters that should be
carefully compared. A longitudinal study of the resulting commit-
ment of hESC-derived neural progenies according to their pre-
transplantation maturation stage revealed that the influence of
the post-ischemic environment is strictly dependent on the devel-
opmental stage at the time of transplantation (Seminatore et al.,
2010). Early NPC grafts, which still contain neuro-epithelial cells,
producedmore cystic cavities, which indicates epithelial fate, after
transplantation into a severe ischemic lesion than into a mild one,
suggesting a de-differentiation potential of the environment. This
sensitivity was lost in more differentiated NPC, which produced
GABAergic homotopic neurons independently of the severity of
the lesion. Further confirmation of the importance of differen-
tiation before transplantation comes from a comparison of the
fate of early neuro-epithelial cells from fetal hippocampus after
transplantation into the fetal cortex, and into the lesioned or unle-
sioned adult cortex (Sheen et al., 1999). Cortical neurons were
observed only after in utero transplantation. Transplantation into
the adult environment resulted in production of glial cells and
a notable absence of neurons. A clear relationship was observed
in this study between the absence of neurotrophin receptors on
neuro-epithelial cells and the absence of competency to respond
to surrounding cues. Altogether, these results show that the fate
of NPC transplanted into the lesioned brain is, for a large part,
independent of environmental molecular control, and has more
to see with the intrinsic developmental stage of the cells at
transplantation.
REQUIREMENT 3: INTEGRATION INTO HOST STRUCTURES
For long-term efficacy of grafted cells, it can be reasonably
considered that cells have to go beyond survival and differ-
entiation into accurate cell types, to rebuilt impaired circuits,
unless they are used only for their ability to release a medi-
ator. It has for long been considered that, on the one hand,
the adult brain was not permissive to axonal growth from
exogenous cells and, on the other hand, that transplanted neu-
rons would not receive sufficient signals from the host brain
to understand where to send their axons. Cumulative experi-
mental evidence has challenged this dogma over the last three
decades, showing rewiring and stimulation of brain adaptive plas-
ticity following transplantation, in correlation with functional
improvements.
Lessons from experimental studies
A large body of literature converges to show the efficacy of intrac-
erebral transplantation at functional level. Reversal of motor,
sensorimotor, and cognitive deficits has been reported in all mod-
els of neurological disorders. The structural support for these
improvements is less clear. For instance, the possibility for grafted
neural precursors to reestablish disrupted circuits in the adult
brain has been a matter of controversy (Gonzalez et al., 1988;
Isacson et al., 1988; Wictorin et al., 1989; Guitet et al., 1994;
Sorensen et al., 1996). Strategies have even been devised to help
new axons grow toward correct target sites, mainly through tissue
engineering with biodegradable scaffolds. However, an increasing
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FIGURE 2 | Human neuronal precursors grafted into the post-ischemic
striatum project onto the host substantia nigra, a normal target of
medium spiny GABAergic neurons. Green: MTCO2, a maker of human
fibers; Red: TH, a marker of substantia nigra dopaminergic neurons. Scale
bar: 20μm.
number of studies converge to show that grafted neural pro-
genitors are able to adopt correct phenotypes with regards to
the missing populations, and to send axons toward deafferented
targets. Gaillard et al. have revealed the possibility for cortical
neurons from fetal mouse to restore a point-to-point connec-
tion with sensorimotor and motor targets in the recipient cortex,
thalamus, and spinal cord, by growing axons that were prop-
erly myelinated by host oligodendrocytes (Gaillard et al., 2007).
After grafting hiPSC-derived NPC in a stroke-induced striatal
lesion, we observed a very specific sprouting of the GABAergic
medium spiny neurons generated by the graft to the host SN,
suggesting reconstruction of the striato-nigral loop (Figure 2;
Polentes et al., personal communication). These results suggest
that, beyond the ability to grow axons over long distances, neu-
ral progenitors are actually able to recognize molecular cues
present in the adult brain after an acute lesion. This has important
implications for future application of SC therapy in ischemic or
traumatic insults.
Lessons from clinical studies
A major result from clinical trials performed for patients with
neurodegenerative diseases since the 1980 is that grafted neu-
roblasts and/or NSCs from human fetal tissue survive for years
and restore local function in the grafted brain, indirectly sug-
gesting integration and interaction with host brain structures
(Lindvall and Björklund, 2011). The functionality of dopamin-
ergic precursors grafted in Parkinson’s patients has also been
assessed by both dopamine release, ability to uptake the tracer
[18F]dopa andmaintenance of post-synaptic D2 dopamine recep-
tors (Piccini et al., 1999). Trials with PSC are quite recent, and no
data are yet available on the behavior of intracerebrally grafted
neural derivatives from PSC. The first trials with selected SC
have been performed in stroke patients. In 2000, Kondziolka and
collaborators reported the initial results of a pilot trial for 12
patients with basal ganglia stroke using the NTN2 neural cell line
(Kondziolka et al., 2000). Autopsy on one patient 27 months after
implantation confirmed that grafted cells had survived (Nelson
et al., 2002). In six patients, increased positron emission tomog-
raphy (Meltzer et al., 2001), correlated with improvement in
the European Stroke Scale (Kondziolka et al., 2000), suggested
functionality of the cells. Improvements in specific tests were
also observed in a phase II randomized open-label trial with
the same cell line (Kondziolka et al., 2005). Development of
diffusion tensor imaging will be quite helpful in the future to
define the extent of axonal sprouting and target innervation by
grafted cells.
Although graft-host interactions can hardly be approached in
grafted patients, noteworthy demonstrations of host-graft inter-
actions have been recently provided from grafted Parkinson’s and
Huntington’s disease patients. Both examples show that the recip-
rocal dialogue that establishes between grafted cells and their
surrounding diseased tissue might have important consequences
on both.
Parkinson’s disease was the first neurological disorder to ben-
efit from intracerebral transplantation. The possibility of prop-
agation of the disease to transplanted cells was reported on
deceased patients with 11–16 years post-transplantation delays.
Hopefully in a very small proportion (1–4%), grafted dopamin-
ergic neurons contained a-synuclein-rich Lewy bodies and Lewy
neurites characteristic of the disease. A number of mechanisms
have been evoked to explain the transmission of clinical charac-
teristics to unaffected exogenous cells, including inflammation,
oxidative stress, excitotoxicity, reduced levels of trophic factor
and a protein-mediated mechanism (Brundin et al., 2008). This
observation has, so far, remained isolated.
Huntington’s disease clinical trials with transplantation are
more limited (Nicoleau et al., 2011). Autopsy results from three
patients have been published (Cicchetti et al., 2009) that revealed
surviving grafts 10 years after transplantation. In two patients,
grafts had formed striatal-like tissue and contained neurons with
markers of mature striatal projection neurons and interneu-
rons, none of which contained the Huntingtin aggregates typ-
ical of the disease. However, in a phase II multicentric-center
study, grafting was found to elicit an alloimmmunisation reac-
tion from the recipient in half of the patients (Krystkowiak
et al., 2007). Alloimmunisation is an immune reaction of the
host to antigens expressed by an individual of the same species
that might progressively lead to graft rejection. Although this is
not directly a response of grafted cells to environmental cues, it
shows the capacity of grafted cells to elicit a dramatic response
in their host.
CONCLUSION
PSCs hold the potential to revolutionize the field of neuro-
regenerative medicine by offering a robust and flexible source
of allogenic or HLA-compatible neural precursors. Key achieve-
ments have been performed regarding our ability to control
neuronal fate in vitro and the capacity of hPSC-derived neural
progenitors to engraft into a host brain has been demonstrated
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up to the level of circuit reconstruction. However, many
challenges remain to be dealt with to fully validate the use of
hPSC as a routine source of cells for replacement strategies.
In particular, the relationships between the observed functional
effects and the degree of integration of grafted cells into the host
circuitry deserve full characterization. The development of imag-
ing techniques, in particular of diffusion tensor imaging, should
allow fiber tracking and a better characterization of the extent
of rewiring and fiber development after grafting into the human
brain.
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